Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
FX Shoulder Prospective Clinical Study
Recruiting
Prospective Multi-Center Registry on study subjects with implanted devices marketed and legally commercialized in the USA by FX Shoulder Solutions.
Gender:
ALL
Ages:
All
Trial Updated:
10/05/2023
Locations: First Settlement Orthopedics, Marietta, Ohio
Conditions: Osteoarthritis Shoulder, Rotator Cuff Syndrome of Shoulder and Allied Disorders, Fracture, Shoulder
LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC
Recruiting
The study evaluates the efficacy and safety of two strengths of LUT014 Gel topically applied once a day for 4 weeks, compared to placebo, in metastatic colorectal cancer (mCRC) patients who developed Grade 2 or non-infected Grade 3 EGFRI induced acneiform lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2023
Locations: The Christ Hospital, Cincinnati, Ohio
Conditions: EGFRI Induced Acneiform Lesions
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
Recruiting
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2023
Locations: Integrated Pain Specialists, Columbus, Ohio
Conditions: Urinary Incontinence, Urge
Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection
Recruiting
C-diff infection often causes belly pain and diarrhea and can be very hard to treat with medicine. One of the possible reasons that C-diff infection is hard to treat is because there is too much "bad" bacteria in the colon. Investigators believe that putting more "good" bacteria into the colon will help fight the "bad" bacteria. We do this by doing a fecal (poop) transplant. Fecal transplant has been done at other hospitals, but not at Nationwide Children's Hospital. Since our Investigators hav... Read More
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
09/28/2023
Locations: GI Division, Nationwide Children's Hospital, Columbus, Ohio
Conditions: Clostridium Difficile
Phase 2a Multiple Ascending Dose Study in Hospitalized Patients With Pneumonia.
Recruiting
A Phase 2a, randomized, double-blind, placebo-controlled, multiple ascending dose study in patients who are hospitalized with presumed pneumonia requiring supplemental oxygen therapy. The purpose of this study is to examine the safety, tolerability and efficacy of AV-001 Injection administration daily to the earlier of day 28 or EOT (day prior to hospital discharge). A total of 120 eligible patients (20 patients in each of cohort 1, 2 and 3 and 60 patients in cohort 4) will be recruited from up... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: The Ohio State University, Columbus, Ohio
Conditions: Acute Respiratory Distress Syndrome, COVID-19 Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Recruiting
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
Gender:
ALL
Ages:
35 years and above
Trial Updated:
09/26/2023
Locations: Glaukos Investigator Site, Cincinnati, Ohio
Conditions: Glaucoma
Biomarkers of Acute Stroke in Clinic
Recruiting
The proposed study will investigate the clinical use of the ISCDX test that may differentiate between diverse stroke etiologies as listed below: Aim 1: Differentiate between cardioembolic and large artery atherosclerotic ischemic strokes, when hemorrhagic stroke is ruled out, as defined by TOAST classification of subtypes of acute ischemic stroke. Aim 2: In cases of ischemic strokes of unknown or "cryptogenic" etiology, determine the ability of biomarker blood tests to predict etiology between... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
09/26/2023
Locations: Ohio Health Riveside Methodist Hospital, Columbus, Ohio
Conditions: Ischemic Stroke, Ischemia, Atrial Fibrillation, Transient Ischemic Attack, Transient Cerebrovascular Events, Thrombotic Stroke, Stroke, Stroke, Acute, Stroke, Ischemic, Stroke, Complication, Stroke of Basilar Artery, Atherosclerosis, Atheroma, Cardioembolic Stroke, Cardiomyopathies, Cardiovascular Stroke, Thromboembolism
Shwachman Diamond Syndrome Registry and Study
Recruiting
Shwachman-Diamond syndrome (SDS) is a genetic condition characterized by bone marrow failure, medical co-morbidities, and leukemia predisposition. SDS-Like patients share clinical features with SDS but lack mutations in known SDS genes. Since SDS/SDS-Like syndromes are rare diseases, data are sparse regarding the clinical features, natural history, clinical outcomes with current management, and treatment. For this reason, the SDS Registry was formed to collect clinical data from medical records... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/25/2023
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Shwachman-Diamond Syndrome, Shwachman-Diamond Syndrome-Like
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Gabrail Cancer Center, Canton, Ohio
Conditions: Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
Recruiting
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS or EGFR mutations to determine the maximum tolerated dose and recommended Phase II dose of HBI-2376 and characterize its pharmacokinetic profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2023
Locations: Gabrail Cancer Center, Canton, Ohio
Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Cancer, Cancer of Pancreas, Cancer of Colon
Cricopharyngeal Dysfunction and Esophageal Diverticulum
Recruiting
Patients undergoing open transcervical or endoscopic approach in which a laser or stapler is used to divide the common wall between the diverticulum and esophagus, or who are not surgical candidates but agree to follow-up.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/12/2023
Locations: UC Health Otolaryngology-Head and Neck Surgery, Cincinnati, Ohio
Conditions: Zenker Diverticulum, Progressive Dysphagia, Pharyngoesophageal Diverticulum
Evaluate the Safety and Pharmacokinetic Profile of ETR028 and ETR029 in Healthy Adult Subjects
Recruiting
The goal of this Phase 1 clinical study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of O2P (Oral Overdose Protected) hydrocodone prodrugs (ETR028 and ETR029) relative to hydrocodone bitartrate hemipentahydrate (HCBT) comparator following single oral doses in healthy adult subjects under fasted and fed conditions with naltrexone blockade
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
09/11/2023
Locations: Medpace, Cincinnati, Ohio
Conditions: Acute Pain